CSPC’s Anbenitamab Regimen Cuts Death Risk 61% in Phase III Gastric Cancer Trial

• CSPC Pharmaceutical Group presented updated Phase III results for anbenitamab at the ESMO Congress on October 23, 2026.
• Anbenitamab with chemotherapy improved survival versus standard care in HER2-positive advanced gastric or gastroesophageal junction cancer following unsuccessful trastuzumab treatment.
• The combination also delayed disease progression, with manageable safety risks.
• No treatment-related deaths occurred in the anbenitamab group, compared with five in the control group.
• China granted marketing approval in May 2026 for anbenitamab, branded Ennituo, with chemotherapy as a second-line or later treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12383436), on October 26, 2026, and is solely responsible for the information contained therein.